Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00002663 · OUTCOME

Clinical Benefit Rate (CBR)

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies · Source last updated 2023-02-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
From Day 1 through 251.1 months after Day 1 dose

What was measured

The CBR was the proportion of participants who have achieved a CR, PR or SD assessed at least 28 days after first dose date of study drug. For participants with clinically and/or radiologically evident EBV LPD or malignancies, CR as complete resolution of all clinical and radiologic evidence of lymphoma, confirmed by biopsy of affected tissues when indicated, lasting for at least 3 weeks following completion of a cycle of tabelecleucel or EBVCTLs; and a PR as a \>= 50% reduction in size of all lymphomatous lesions as determined by CT or MRI scan measurements of tumor volume, maintained for at least 3 weeks following completion of a cycle of tabelecleucel or EBV-CTLs. For participants without clinically and/or radiologically evident tumors with increasing levels of EBV DNA, CR as clearance of EBV without subsequent development of EBV+ LPD; and PR as at least a 10-fold decrease in EBV DNA levels. The CBR was included specifically as clinically meaningful for solid tumor, namely LMS.

Analysis population: Full analysis set included all participants who received at least one dose of study treatment (tabelecleucel or EBV-CTLs). Participants who achieved CR, PR or SD were analyzed for this outcome measure. Results from arms with \<= 3 participants (as shown in the participant flow) are excluded due to the low numbers of participants; these low numbers pose a risk for participant re-identification in these rare indications of this single center study.

Groups in this outcome

EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only)

Participants with EBV+ PTLD following HCT who were R/R to rituximab received IV infusion of tabelecleucel on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.

EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only)

Participants with EBV+PTLD following SOT who were R/R to rituximab and chemotherapy received IV infusion of tabelecleucel on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.

EBV+ LMS (Tab-cel Only)

Participants with EBV+ following LMS received IV infusion of tabelecleucel on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.

EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only)

Participants with EBV+PTLD following HCT who were R/R to rituximab or rituximab naive received donor-derived EBV-CTL on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.

EBV+ Viremia (EBV-CTLs Only)

Participants with EBV+ following viremia received donor-derived EBV-CTLs on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only)11
EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only)4
EBV+ LMS (Tab-cel Only)5
EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only)23
EBV+ Viremia (EBV-CTLs Only)7

Reported measurements

Source class 1
Values in Percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only)63.6Not reported30.889.1Not reported
EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only)75.0Not reported19.499.4Not reported
EBV+ LMS (Tab-cel Only)80.0Not reported28.499.5Not reported
EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only)47.8Not reported26.869.4Not reported
EBV+ Viremia (EBV-CTLs Only)71.4Not reported29.096.3Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        30.8
        upper Limit
        89.1
        value
        63.6
      2. group Id
        OG001
        lower Limit
        19.4
        upper Limit
        99.4
        value
        75.0
      3. group Id
        OG002
        lower Limit
        28.4
        upper Limit
        99.5
        value
        80.0
      4. group Id
        OG003
        lower Limit
        26.8
        upper Limit
        69.4
        value
        47.8
      5. group Id
        OG004
        lower Limit
        29.0
        upper Limit
        96.3
        value
        71.4
denoms
  1. counts
    1. group Id
      OG000
      value
      11
    2. group Id
      OG001
      value
      4
    3. group Id
      OG002
      value
      5
    4. group Id
      OG003
      value
      23
    5. group Id
      OG004
      value
      7
    units
    Participants
description
The CBR was the proportion of participants who have achieved a CR, PR or SD assessed at least 28 days after first dose date of study drug. For participants with clinically and/or radiologically evident EBV LPD or malignancies, CR as complete resolution of all clinical and radiologic evidence of lymphoma, confirmed by biopsy of affected tissues when indicated, lasting for at least 3 weeks following completion of a cycle of tabelecleucel or EBVCTLs; and a PR as a \>= 50% reduction in size of all lymphomatous lesions as determined by CT or MRI scan measurements of tumor volume, maintained for at least 3 weeks following completion of a cycle of tabelecleucel or EBV-CTLs. For participants without clinically and/or radiologically evident tumors with increasing levels of EBV DNA, CR as clearance of EBV without subsequent development of EBV+ LPD; and PR as at least a 10-fold decrease in EBV DNA levels. The CBR was included specifically as clinically meaningful for solid tumor, namely LMS.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants with EBV+ PTLD following HCT who were R/R to rituximab received IV infusion of tabelecleucel on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    EBV+ PTLD-HCT R/R Rituximab (Tab-cel Only)
  2. description
    Participants with EBV+PTLD following SOT who were R/R to rituximab and chemotherapy received IV infusion of tabelecleucel on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
    id
    OG001
    title
    EBV+ PTLD-SOT R/R Rituximab + Chemo (Tab-cel Only)
  3. description
    Participants with EBV+ following LMS received IV infusion of tabelecleucel on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
    id
    OG002
    title
    EBV+ LMS (Tab-cel Only)
  4. description
    Participants with EBV+PTLD following HCT who were R/R to rituximab or rituximab naive received donor-derived EBV-CTL on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
    id
    OG003
    title
    EBV+ PTLD-HCT R/R Rituximab (EBV-CTLs Only)
  5. description
    Participants with EBV+ following viremia received donor-derived EBV-CTLs on Days 1, 8, and 15 and were observed for 3 weeks. After the observation period, additional courses (2 courses) may have been provided in the absence of disease progression or unacceptable toxicity.
    id
    OG004
    title
    EBV+ Viremia (EBV-CTLs Only)
param Type
NUMBER
population Description
Full analysis set included all participants who received at least one dose of study treatment (tabelecleucel or EBV-CTLs). Participants who achieved CR, PR or SD were analyzed for this outcome measure. Results from arms with \<= 3 participants (as shown in the participant flow) are excluded due to the low numbers of participants; these low numbers pose a risk for participant re-identification in these rare indications of this single center study.
reporting Status
POSTED
time Frame
From Day 1 through 251.1 months after Day 1 dose
title
Clinical Benefit Rate (CBR)
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice